Related references
Note: Only part of the references are listed.Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
Kirsi M. Manz et al.
ADVANCES IN THERAPY (2020)
A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
Christos Fountzilas et al.
BRITISH JOURNAL OF CANCER (2020)
Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma
Allen Jacob et al.
FUTURE ONCOLOGY (2020)
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma
Sumanta K. Pal et al.
EUROPEAN UROLOGY (2020)
Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Mary E. Westerman et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Tivozanib in renal cell carcinoma: a new approach to previously treated disease
Nicholas J. Salgia et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients
Suresh Gopi Kalathil et al.
ONCOIMMUNOLOGY (2020)
TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The role of tivozanib in advanced renal cell carcinoma therapy
Bernard Escudier et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Jayashree Kalpathy-Cramer et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review
Simone A. M. Badal et al.
CURRENT DRUG TARGETS (2017)
Renal cell carcinoma: Review of etiology, pathophysiology and risk factors
Nadezda Petejova et al.
BIOMEDICAL PAPERS-OLOMOUC (2016)
Recent advances in renal cell carcinoma from a pathological point of view
Shuji Mikami et al.
PATHOLOGY INTERNATIONAL (2016)
Design, synthesis and biological evaluation of deuterated Tivozanib for improving pharmacokinetic properties
Shiwei Guo et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tivozanib: Status of Development
Muhammad Omer Jamil et al.
CURRENT ONCOLOGY REPORTS (2015)
Effects of Ketoconazole or Rifampin on the Pharmacokinetics of Tivozanib Hydrochloride, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor
Monette M. Cotreau et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2015)
Management of metastatic kidney cancer in the era of personalized medicine
Jose G. Monzon et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2014)
Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial
Amikumar Mehta et al.
FUTURE ONCOLOGY (2014)
Renal cell carcinoma
Eric Jonasch et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
M. N. Fishman et al.
EUROPEAN JOURNAL OF CANCER (2013)
Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951)
Brigitte C. M. Haberkorn et al.
FUTURE ONCOLOGY (2013)
Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
C. Lance Cowey
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
Dmitry A. Nosov et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1,-2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
Ferry A. L. M. Eskens et al.
CLINICAL CANCER RESEARCH (2011)
The Epidemiology of Renal Cell Carcinoma
Borje Ljungberg et al.
EUROPEAN UROLOGY (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
Pankaj Bhargava et al.
CURRENT ONCOLOGY REPORTS (2011)
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Virginia E. Kwitkowski et al.
ONCOLOGIST (2010)
Temsirolimus, an inhibitor of mammalian target of rapamycin
Brian I. Rini
CLINICAL CANCER RESEARCH (2008)
Axitinib for renal cell carcinoma
Guru Sonpavde et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
mTOR pathway in renal cell carcinoma
Sara C. Hanna et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties
Kazuhide Nakamura et al.
CANCER RESEARCH (2006)
Everolimus - A review of its use in renal and cardiac transplantation
C Dunn et al.
DRUGS (2006)
The changing natural history of renal cell carcinoma
AJ Pantuck et al.
JOURNAL OF UROLOGY (2001)
Share Paper
